Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: StockDung who wrote (4649)	10/7/2003 2:32:04 AM
From: Mad2	Read Replies (1) \| Respond to of 5582

Here's a bit of info on R. Steven Davidson (guys whose name start with a initial should always be suspect of something). PHd and MBA from American University of Asturias So far I've found that American University of Asturias is affiliated with St George University International (whose registered head office is in Nevis, West Indies. Here's their degree program stgeorgeuniversity.edu Not comming up with much on Dr. Davidson's alma mater R. Steven Davidson, Ph.D., MBA President, Chief Executive Officer and Director R. Steven Davidson, Ph.D., MBA, has served as the president and chief executive officer of Zengen since January 2002 and is currently on the board of directors. As president and CEO, Dr. Davidson is responsible for building a team of individuals with the skills to fully leverage the Company’s patented peptide technologies in both the pharmaceutical and over-the-counter industries. Prior to joining Zengen, Dr. Davidson was the co-founder, chief executive officer and a director of Gel Tech, LLC. At Gel Tech, he was instrumental in raising capital for the market launch and distribution of Zicam® Cold Remedy. He is also one of the inventors of Zicam®. Dr. Davidson led the marketing team that propelled Zicam® to prominence, making it one of the top medications in its class. He also implemented and launched line extensions to strengthen the brand name and increase company value. Previously, Dr. Davidson served as the managing director of Biodelivery Technologies, Inc. and was the chief executive officer of Biotem Cytotechnologies, Inc., a biopharmaceutical research and development company. He received his doctorate in biopharmaceutical project management and his MBA in international finance from the American University of Asturias. He conducted post-graduate studies at Villanova University. zengen.com